Now, a groundbreaking discovery by UC Davis graduate student Kateryna Feoktistova and Assistant Professor Christopher Fraser illuminates the way that the protein, eukaryotic initiation factor 4E (eIF4E), acts upon cancer-promoting messenger RNA molecules. When translated, this type of mRNA can trigger the runaway cell replication that results in malignancies.
Published in the August 13 edition of the Proceedings of the National Academy of Sciences, the results solve a decades-long scientific mystery and may lead to new, highly specific cancer treatments that will act only on growth-promoting cells as opposed to all cells.
"This protein is one the most important initiation factors in this cellular pathway, and there is a lot of energy in the cell that goes into regulating the level and availability of it," Fraser said. "To suddenly find this function is quite a transformative idea in the field; people can now try and study this new activity and its relation to growth-promotion and cancer."
With elevated eIF4E levels found in 30 percent of all major cancers, the protein is already a target of pharmaceutical research. Clinical trials are currently underway for drugs that act upon eIF4E's long-known function of binding the cap at the head of all mRNA.
But the protein's cap-binding activity doesn't fully explain its relationship to cancer.
Feoktistova and Fraser solved that mystery while studying a region at the head of mRNA strands, where many cancer-promoting mRNA are much more complex than typical mRNA. In the cancer-promoting variants, a highly knotted region at the start of the strand must be unwound before a ribosome can bind and begin translating the genetic code into the amino acids that build our cellular proteins.
Usually that knotted region prevents most of the ribosomes from starting the process, so cancer-promoting mRNAs aren't translated effectively. But when high levels of eIF4E are present the 4E binds to a complex that activates another protein, 4A, which then is able to unwind the knot and translate the genetic code into proteins that can trigger tumor growth.
The man who originally discovered eIF4E in 1978, Professor Nahum Sonenberg of McGill University, expressed his enthusiasm for what he calls "logical, beautiful" research.
"This is really a big discovery -- it explains a lot of the biology that we have. At the beginning of my talks I used to emphasize that mRNAs are eIF4E-sensitive, but people would ask 'how does it work?' and I never had an answer," Sonenberg said. "In the last month, I have been able to mention Chris Fraser's paper and finally provide an explanation.
"It has made my life much easier," he joked.
Feoktistova, a fifth-year Ph.D. student who also got her undergraduate degree at UC Davis, made the breakthrough when she purified the individual components of eIF4E's larger protein complex and then observed the complex's activity with individual parts missing. It was during this process that she first noticed 4E's stimulation of 4A.
"Without 4E, the complex wasn't active. People hadn't studied it without 4E before because its individual protein components were very hard to separate," Feoktistova said.
Fraser added that it is necessary to maintain an interaction between 4E and the complex containing 4A in order to complete the unwinding.
"If you lose this connection, you stall the complex," he said. "But if you have a lot of 4E floating around in the cell, and the complex loses a 4E, another one can be easily found" (see illustration).
Now researchers can add the stimulation of 4A and its unwinding activity to 4E's long-known – and totally separate – cap-binding activity.
"Textbooks are likely to be revised once the finding is confirmed given the fundamental importance of this protein in cell physiology and the fact that essentially nothing new has been discovered regarding its function for several decades," College of Biological Sciences Dean James E. K. Hildreth said.
Fraser and Feoktistova's next steps will be to study the ways that 4E, 4A, and the rest of the complex work together translate mRNA.
The work was funded by grants from the National Institutes of Health.
Andy Fell | EurekAlert!
Making fuel out of thick air
08.12.2017 | DOE/Argonne National Laboratory
08.12.2017 | Technische Universität Dresden
08.12.2017 | Event News
07.12.2017 | Event News
05.12.2017 | Event News
08.12.2017 | Life Sciences
08.12.2017 | Information Technology
08.12.2017 | Information Technology